Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Mesoblast Limited ( (AU:MSB) ) has issued an announcement.
JPMorgan Chase & Co. and its affiliates have ceased to be substantial holders in Mesoblast Limited, a company involved in the development of regenerative medicine products. The change in their substantial holding status is due to various transactions involving securities lending, purchasing, and sales, as well as the rehypothecation of client securities. This shift in holdings may impact Mesoblast’s market perception and investor confidence, as JPMorgan’s involvement was significant in terms of voting securities.
The most recent analyst rating on (AU:MSB) stock is a Buy with a A$3.11 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
More about Mesoblast Limited
Average Trading Volume: 5,377,053
Technical Sentiment Signal: Buy
Current Market Cap: A$3.7B
See more insights into MSB stock on TipRanks’ Stock Analysis page.